Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.78 | 0.75 | 3.34 |
| EPS, GAAP | 0.60 | 0.89 | 0.89 |
| Consensus Estimate | 1.32 | 1.05 | 25.71 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 3.43 | 2.58 | 33.09 |
| EPS, GAAP | 3.30 | 2.85 | 15.97 |
| Consensus Estimate | 4.90 | 3.79 | 29.29 |
| CELG | Industry Average | |
| P/E (TTM) | 34.55 | NA |
| P/E (Forward) | 20.50 | NA |
| PEG Ratio | 0.83 | 2.19 |
| Price/Sales | 9.21 | 18.50 |
| Beta | 0.83 | 0.70 |
| 7:44 AM | 4/4/2013 | Cyclacel Agrees to Sell Patents to Celgene; Litigation to Be Dismissed |
| 3:36 PM | 3/15/2013 | UPDATE: Onyx Pharmaceuticals CEO: Seeking Acquisition Targets |
| 4/5/2013 | Top Analyst Upgrades and Downgrades (CELG, CMCSA, FB, FFIV, JPM, JNPR, KMB, NWSA, PDCE, AET, CI, HUM, UNH, WLP) (24/7 Wall St) |
| 3/2/2013 | Celgene Drug Results Fall Short of Earlier Trial (WSJ.com) |
| 3/4/2013 | Research Reports (Barrons.com) |
| 2/28/2013 | ETF Folly: Biotech ETFs, Nothing but Confusion (24/7 Wall St) |
| 2/20/2013 | Major Companies Hitting All-Time Highs! (AWK, AWR, BRK-B, UNP, HON, MMM, CELG, GOOG, CL, KMB, PG, CLX, URI, DIS) (24/7 Wall St) |
| 2/20/2013 | Celgene: When Biotechs Use Stock Buybacks to Juice Price and Earnings (24/7 Wall St) |
| 2/11/2013 | Don't Sell Celgene (Barrons.com) |
| 2/11/2013 | Stocks to Watch: Novo Nordisk, US Airways, Radian Group (WSJ.com) |
